Managing antipsychotic-induced tardive dyskinesia
| Autor: | George Gardos |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Pediatrics
medicine.medical_specialty Dyskinesia Drug-Induced medicine.drug_class medicine.medical_treatment Atypical antipsychotic Neurological disorder Toxicology Tardive dyskinesia mental disorders otorhinolaryngologic diseases medicine Humans Pharmacology (medical) Antipsychotic Clozapine Pharmacology Dystonia business.industry medicine.disease Abnormal involuntary movement nervous system diseases Dyskinesia Anesthesia medicine.symptom business medicine.drug Antipsychotic Agents |
| Zdroj: | Drug safety. 20(2) |
| ISSN: | 0114-5916 |
| Popis: | Antipsychotic-induced tardive dyskinesia is a common and clinically significant hazard of long term antipsychotic therapy. The arrival of atypical antipsychotics has markedly improved the outlook: atypical antipsychotics are emerging as effective treatments and may also reduce the prevalence and incidence of tardive dyskinesia. In mild cases, careful monitoring of tardive dyskinesia by serial Abnormal Involuntary Movements Scale (AIMS) assessments may be the appropriate course. More severe tardive dyskinesia calls for intervention in order to treat the dyskinesia. Atypical antipsychotics and tocopherol (vitamin E) are effective and generally well tolerated treatment options for tardive dyskinesia. Tardive dyskinesia variants such as tardive dystonia and tardive akathisia tend to be more severe and difficult to treat compared with typical tardive dyskinesia. Prevention of tardive dyskinesia is possible through careful selection of patients for antipsychotic therapy, use of the lowest effective antipsychotic dosages, use of atypical rather than traditional antipsychotics and concurrent tocopherol administration. The clinician can now undertake the management of tardive dyskinesia with growing confidence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink